Mélanie

@MelClaps

MD, Medical Oncologist, Physician #GUcancer #Research

Katılım Ekim 2019

41 Takip Edilen34 Takipçiler

Mélanie retweetledi

Giuseppe Procopio@g_procopio_·22 Oca

More about #RareHistology GU tumors at @IstTumori: update on academic trials by @MelClaps and multidisciplinary discussion because rare doesn’t mean less important. #ClinicalResearch #Oncology #Genitourinary #ScientificEvent #ControversiesinGU2026

English

123

Mélanie@MelClaps·22 Mar

Our research on #renalcellcarcinoma: prospective data about #TKI efficacy after #immunecheckpointinhibitors #sequencestrategy #cabozantinib #secondline #ccRCC doi: 10.1177/03008916221138881 @gippo27 @elena_verzoni @pierangelasepe @UgoDeGiorgi @DrIacovelli @meeturoIT

Tumori Journal@TumoriJ

🎙️ #Podcast Dr Mélanie Claps and Dr Giuseppe Procopio discuss about the results of the Breakpoint Trial evaluating efficacy and safety of #cabozantinib for patients with metastatic #renalcellcarcinoma👇 🎙️traffic.libsyn.com/secure/sagecli… To the article 🔗journals.sagepub.com/doi/full/10.11… #kcsm

English

325

Mélanie retweetledi

Meet-URO@meeturoIT·15 Şub

Ready for @ASCO #GU23! Here's Meet-URO selection of the hot topics and key presentation. Looking forward to exciting data presented in San Francisco. Congrats to the @meeturoIT group for the selected works!

English

870

Mélanie retweetledi

Tom Powles@tompowles1·18 Şub

COSMIC313 cabo/ipi/nivo vs ipi/nivo in 1st line RCC. ⬆️ FU & ⬆️ numbers show continued strong PFS signal:HR 0.74.Exploratory analysis show benefit for triplet mainly in intermediate risk .This is not due to ⬇️ drug exposure. Maybe VEGF treatment ⬇️ active in poor risk #GU23

English

146

27.2K

Mélanie@MelClaps·17 Şub

Proud of being part of this Team 😎 #collectingductcarcinoma #rarecancer #renalcancer #research

Tumori Journal@TumoriJ

Collecting duct carcinoma is a rare type of non–clear cell renal cell carcinoma Authors present analysis from BONSAI-2⃣ study👉#Nivolumab as therapeutic option after #cabozantinib failure in #mCDC Pts 🔗journals.sagepub.com/doi/full/10.11… @gippo27 @MelClaps @pierangelasepe @elena_verzoni

English

227

Mélanie retweetledi

Tumori Journal@TumoriJ·29 Oca

Dr Mélanie Claps, @IstTumori GU Cancers Unit, about👇 Multicenter phase2⃣ single arm study of #cabozantinib in Pts w/ advanced or unresectable #renalcellcarcinoma pre-treated w/ one immune-checkpoint inhibitor ➡️ The BREAKPOINT trial (Meet-Uro trial 03) journals.sagepub.com/doi/full/10.11…